ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosomes technologies, announces that the Company’s CSO, Dr Randolph Corteling, has presented new data at the Extracellular Vesicle-Based Therapeutic Development Summit in Boston, MA, highlighting the significant advantages of the Company’s stem cell derived exosome approach.
ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosome technologies, announces the appointment of John Hawkins, ACA, as Chief Financial Officer (‘CFO’) and ReNeuron Board member with immediate effect. The Group is also pleased to announce that Simon Dew will be joining the Executive Team as Chief Business Officer (‘CBO’).
Additionally, the Group is making changes to the Executive team.
ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosome technologies, announces that at the Annual General Meeting (AGM) held earlier today, all resolutions were duly passed.
ReNeuron Group plc (AIM: RENE), a UK-based stem cell leader in stem cell derived exosome technologies, announces that its Annual Report and Accounts for the year ended 31 March 2022 and the Notice of the 2022 Annual General Meeting (“AGM”) have today been sent to shareholders and are also available on the Company’s website.
01 August 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosome technologies, announces the appointment of Catherine Isted, ACMA, as Chief Executive Officer (“CEO”), effective 1 September 2022.
Strategic shift to fully focus on ReNeuron’s Proprietary Exosomes Platform
04 July 2022: ReNeuron Group plc (AIM: RENE), a UK based leader in stem cell derived exosome technologies, announces its preliminary results for the year ended 31 March 2022.
ReNeuron has negotiated a Supplemental Terms Agreement with potential to generate revenue of up to £6m
01 July 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell and Exosomes Technologies, is pleased to announce that it has negotiated and signed a Supplemental Terms Agreement with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196. SH, 02196. HK) which has the potential to generate revenues of up to £6m for the Company.
20 June 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell and Exosomes Technologies, will announce its preliminary results for the year ended 31 March 2022 on Monday 4 July 2022.
3 May 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell and Exosomes Technologies, announces that the Company will be attending the International Society of Cell and Gene Therapy Annual Meeting (ISCT 2022) from the 4-7 May in San Francisco, California.
22 March 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell and Exosomes Technologies, announces that Dr Tim Corn and Mark Evans have resigned as Non-Executive Directors of the Company and that Martin Walton has been appointed as a Non-Executive Director, all with immediate effect.
